Regulation - Alcon

Filter

Current filters:

Alcon

Popular Filters

EMA/CHMP backs Alcon’s Simbrinza for glaucoma

25-05-2014

Swiss drug major Novartis’ eye care division Alcon says that the European Medicines Agency’s Committee…

AlconEuropeNovartisOphthalmicsPharmaceuticalRegulationSimbrinza

First Asian approval for ophthalmic drug Jetrea, in Malaysia

18-04-2014

Belgian biotech firm ThromboGenics NV revealed today that Jetrea (ocriplasmin) has been approved in Malaysia…

AlconAsia-PacificBiotechnologyJetreaMalaysiaNovartisOphthalmicsRegulationThromboGenics

Alcon and ThromboGenics launch Jetrea in Canada

21-11-2013

ThromboGenics NV (Euronext Brussels: THR) and its partner Alcon, the ophthalmic unit of Novartis (NOVN:…

AlconBiotechnologyCanadaJetreaMarkets & MarketingOphthalmicsRegulationThromboGenics

Germany’s G-BA confirms benefits of ThromboGenics’ Jetrea for VMT

18-10-2013

Belgian biotech firm ThromboGenics says that the Final Early Benefit Assessment from the German Federal…

AlconBiotechnologyEuropeJetreaNovartisOphthalmicsPricingRegulationThromboGenics

ThromboGenics' Jetrea gets initial NICE recommendation for VMT

12-06-2013

Belgium-based biopharma company ThromboGenics (Euronext Brussels: THR) said this morning (June 12) that…

AlconEuropeJetreaNovartisOphthalmicsPharmaceuticalPricingRegulationThromboGenics

US FDA approves Alcon's Simbrinza, a fixed-combination therapy for glaucoma

22-04-2013

Swiss drug major Novartis' (NOVN: VX) eye care division Alcon on Friday (April 19) received US Food and…

AlconNorth AmericaNovartisOphthalmicsPharmaceuticalRegulationSimbrinza

EU approval of Jetrea triggers a 45 million-euro milestone for ThromboGenics from Alcon

18-03-2013

The European Commission has approved Swiss drug major Novartis' (NOVN: VX) Alcon ophthalmic unit's Jetrea…

AlconEuropeFinancialJetreaNovartisOphthalmicsPharmaceuticalRegulationThromboGenics

Alcon's Nevanac accepted for NHS use in Scotland

12-11-2012

Ophthalmic specialist Alcon, a part of Swiss drug major Novartis (NOVN: VX), said yesterday that its…

AlconEuropeNevanacNovartisOphthalmicsPharmaceuticalPricingRegulation

FDA advisory panel backs approval of ThromboGenics' ocriplasmin for VMA

29-07-2012

Belgian biopharmaceutical firm ThromboGenics NV (Euronext Brussels: THR) says that the US Food and Drug…

AlconBiotechnologyNorth AmericaNovartisocriplasminOphthalmicsRegulationThromboGenics

Back to top